Kazia Therapeutics (KZIA) Receivables - Other (2018 - 2025)

Kazia Therapeutics has reported Receivables - Other for 8 years, with the latest figure at $202128.1 in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other changed N/A year-over-year to $202128.1; the trailing twelve-month figure through Dec 2025 stood at $202128.1 (changed N/A YoY), and the FY2025 full-year result was $57782.4, down 34.08% from the prior year.
• Receivables - Other for Q4 2025 stood at $202128.1, up from $57782.4 in the prior quarter.
• The five-year high for Receivables - Other was $202128.1 in Q4 2025, with the low at $26039.6 in Q4 2023.
• Historically, Receivables - Other has averaged $75755.0 across 5 years, with a median of $58524.2 in 2021.
• Annual changes were most pronounced in 2022 — Receivables - Other plunged 51.04% — and 2023, when it soared 142.61%.
• Kazia Therapeutics' Receivables - Other stood at $58524.2 in 2021, then sank by 51.04% to $28650.7 in 2022, then dropped by 9.11% to $26039.6 in 2023, then jumped by 236.6% to $87650.3 in 2024, then surged by 130.61% to $202128.1 in 2025.
• The last three Receivables - Other figures came in at $202128.1 (Q4 2025), $57782.4 (Q2 2025), and $87650.3 (Q2 2024), per Business Quant data.